This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Ziresovir in the treatment of RSV

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Ziresovir

  • is a potent, selective, and orally bioavailable Respiratory syncytial virus (RSV) F protein inhibitor
    • RSV is a member of the species Human orthopneumovirus and belongs to the Pneumoviridae genus of the family Pneumoviridae, order Mononegavirales
      • the 15.2 kb non-segmented genome contains 10 mRNA species encoding 11 distinct proteins, including three surface glycoproteins (SH, G, and F) and several proteins (N, P, L, and M2-1) that comprise the viral RNA-dependent RNA polymerase complex (RdRp)
        • the RSV F protein is the class I viral trimeric fusion (F) glycoprotein, which mediates RSV entry in response to binding of the attachment (G) glycoprotein to a host receptor
        • F protein is critical for the fusion of the viral membrane with the cell plasma membrane, leading to infection of the host cells

Study evidence showed that ziresovir treatment reduced signs and symptoms of bronchiolitis in infants and young children hospitalized with RSV infection (2).

Reference:

  1. Huang LM et al. Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial. Influenza Other Respir Viruses. 2023 Jul 25;17(7):e13176.
  2. Zhao S et al. Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection. NEJM 2024;391:1096-1107.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.